GYRE

Business Context and Reporting Period

Company: Targacept, Inc. (Note: Request metadata listed "Gyre Therapeutics," but the filing text identifies the registrant as Targacept, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Targacept is a biopharmaceutical company developing novel NNR Therapeutics (neuronal nicotinic receptor modulators) for nervous system disorders. The company has no internal sales force and relies on strategic collaborations, primarily with AstraZeneca, for the development and commercialization of its product candidates. Its most advanced candidate, TC-5214, is in Phase 3 trials for major depressive disorder.

Key Financial Metrics

Note: The 2010 net income was primarily driven by the recognition of a portion of a $200 million upfront payment received from AstraZeneca in January 2010.

Material Changes vs. Prior Period

• Revenue Surge: Net operating revenues increased by $60.7 million (242%) compared to 2009. This was driven by the recognition of $72.6 million from the AstraZeneca TC-5214 upfront payment and $6.3 million from an amendment to the cognitive disorders agreement.
• Profitability Shift: The company reported a net income of $10.9 million in 2010, reversing a net loss of $39.4 million in 2009. This turnaround is non-recurring and attributable to accounting recognition of deferred revenue rather than operational cash flow from product sales.
• R&D Expense Increase: Research and development expenses rose by $24.4 million (61%) to $64.5 million, reflecting increased costs for Phase 3 clinical trials of TC-5214 and Phase 2 trials for TC-5619 and TC-6987.
• Liquidity Improvement: Cash and investments more than doubled to $252.5 million, bolstered by the $200 million AstraZeneca payment and a $44.4 million public stock offering in October 2009.
• Discontinued Operations: The company discontinued commercialization of its only approved product, Inversine, effective September 30, 2009, resulting in zero product sales revenue in 2010.

Guidance, Outlook, and Risks

Outlook and Milestones:

• TC-5214: Phase 3 trials for major depressive disorder are ongoing. The company expects to file a New Drug Application (NDA) in the second half of 2012. A Phase 2b "switch" monotherapy trial began in Q1 2011.
• TC-5619: Positive Phase 2 results were announced in January 2011 for cognitive dysfunction in schizophrenia. AstraZeneca is expected to decide on licensing TC-5619 in the first half of 2011, which would trigger a $30 million payment.
• AZD3480 & AZD1446: AstraZeneca is expected to make advancement decisions regarding these candidates for ADHD and Alzheimer's disease in the first and third halves of 2011, respectively.

Material Risks and Contingencies:

• Collaboration Dependence: Future revenue and cash flow are heavily dependent on AstraZeneca's decisions to advance, license, and commercialize product candidates. AstraZeneca can terminate the cognitive disorders agreement with 90 days' notice.
• Regulatory Uncertainty: There is no assurance that Phase 3 results for TC-5214 will replicate Phase 2 success. Failure to submit an NDA by September 30, 2012, could jeopardize five-year marketing exclusivity.
• GlaxoSmithKline Termination: In late February 2011, GSK notified Targacept of the termination of their alliance agreement, effective May 2011. The company expects to recognize $18.4 million of deferred revenue from this agreement in Q1 2011.
• Capital Requirements: Management expects existing capital resources to fund operations through the end of 2013, excluding potential milestone payments.

Key Facts for Investor Verification

• Revenue Quality: Verify the sustainability of revenue streams, as 2010 income was largely non-cash accounting recognition of upfront fees rather than product sales.
• AstraZeneca Decisions: Monitor the timing and outcome of AstraZeneca's license decision for TC-5619 (expected H1 2011) and advancement decisions for AZD3480 and AZD1446.
• TC-5214 Phase 3 Data: Confirm the enrollment progress and interim data from the RENAISSANCE Phase 3 program, as failure here would significantly impact the company's valuation.
• Cash Burn Rate: Assess the rate of cash consumption against the $252.5 million cash balance to validate the "through end of 2013" runway estimate.
• Patent Expirations: Review the specific patent expiration dates for key compounds (ranging from 2016 to 2028) to understand the potential commercial window.